UK Markets closed

Addex Therapeutics Ltd (ADDXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.99000.0000 (0.00%)
As of 10:31AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.9900
Open0.9900
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.9900 - 0.9900
52-week range0.9900 - 1.6500
Volume100
Avg. volume0
Market cap32.099M
Beta (5Y monthly)1.37
PE ratio (TTM)N/A
EPS (TTM)-0.4430
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est28.00
  • Globe Newswire

    Addex Announces Participation in the H.C. Wainwright Global Investment Conference

    Geneva, Switzerland, May 19, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will be virtually attending the H.C. Wainwright Global Investment Conference taking place May 23 - 26, 2022. Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate update and discusses recent developments at

  • Globe Newswire

    Addex Announces Participation in the 22nd Bio€quity Europe Conference

    Geneva, Switzerland, May 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, and Dr. Robert Lütjens, Head of Discovery – Biology, will be attending 22nd Bio€quity Europe Conference taking place May 16 - 18, 2022, in Milan, Italy. Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate

  • Globe Newswire

    Addex Shareholders Approve All Resolutions at Annual General Meeting

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10, 2022 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all of the proposals of the board of directors in its 2022 Annual General Meeting (AGM). In line with the Swiss Federal Council COVID-19 Ordinance 3, the company decided to require its shareholders not atten